4basebio client gets approval to start trial in Australia
4basebio
1,316.67p
10:50 21/11/24
Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.
FTSE AIM All-Share
724.62
11:35 21/11/24
Pharmaceuticals & Biotechnology
19,408.88
11:35 21/11/24
The AIM-traded firm said the approval would enable HelixNano to proceed to phase one clinical trials for HN-0001, an mRNA vaccine developed using 4basebio's synthetic DNA technology, ‘opDNA’.
“It’s been a pleasure to work with such an innovative company on their journey to the clinic and we are delighted to see an mRNA vaccine manufactured using 4basebio DNA progressing into patients; this represents another significant milestone for the company,” said the firm’s vice president of research and business development, Dr Amy Walker.
“4basebio has several clients requiring GMP grade DNA and progressing towards clinical trials; we are of course very pleased to be supporting our clients in their clinical programmes.”
At 1529 GMT, shares in 4basebio were up 1.33% at 988p.
Reporting by Josh White for Sharecast.com.